RBC sees big upside for Astex after SGI-110 topline data

|About: Astex Pharmaceuticals, Inc. (ASTX)|By:, SA News Editor

RBC's Michael Yee reiterates an Outperform rating on Astex Pharmaceuticals (ASTX) following topline data from an ongoing trial of SGI-110.

Yee thinks the shares have significant room to run even after the 18% gain the stock has posted premarket — price target is $9.

RBC likes SGI-110 compared to Eisai's (ESALF.PK) Dacogen (indicated for Myelodysplastic syndrome).